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EDITORIAL
Protecting the rights of investigators in industry-
supported clinical research
Robert B. Rutherford, MD,a and K. Wayne Johnston, MD,b Silverthorne, Colo; and Toronto, Canada
THE PROBLEM
Research contracts between a company and a clinical
trial investigator often contain “non-disclosure” clauses,
drawn up to protect the company against the investigator
divulging proprietary information or information about the
company’s business operations. Yet the research contracts
that today’s investigators are asked to sign before partici-
pating in an industry-supported clinical research trial often
contain broadly worded clauses that can be used to restrict
their rights to access, analyze, and report trial data. Typi-
cally, they demand confidentiality by restricting the dissem-
ination of “confidential information,” but in doing so may,
for example, include in the definition of confidential infor-
mation “data developed or generated in whole or part by
the investigator during the research investigation.” Some
clauses prohibit “publication of the results of the research
unless agreed to by the Company in writing.” The latter
restriction may be either without time limits or allowed
under contract only after an inappropriately long period of
time after completion of the research or trial. Such clauses
can create and have created problems for investigators,
probably only a small portion of which has been reported by
them. These problems appear to have recently increased in
number and/or have increasingly become the focus of
journal editorials.1-10
Some of the potential consequences of such restrictive
clauses are more obvious than others. They certainly may
conflict with the scientific goals and integrity of the inves-
tigator. They may also indirectly violate ethics regarding
patient safety as they relate to disclosure of the occurrence
or true incidence of adverse events or lack of efficacy.
Because of a contract’s broad wording, investigators, as
principle authors or coauthors, may be legally prevented
from accessing raw data to check the veracity of data
summaries and statistical analyses performed by the com-
pany. There may be a lack of investigator input into the data
included in or excluded from the summary data set and thus
from publication, with no recourse under the terms of the
contract. Delays or failure to report adverse events or to
report negative trials may result, and the company’s role in
causing these may be justified or defended by the restrictive
terms of many contracts.
Tactics that have been reported as delaying or discour-
aging publication of negative or unfavorable clinical re-
search trials include withholding company approval of a
manuscript submission (based on terms stipulated in the
contract) and dragging out the company review of the
manuscript (which is required by contract), prolonging a
dispute over company-suggested revisions and/or having
another version submitted by other authors in the interim.6
Companies have also withheld raw data needed as back-
ground for a published report.2,10 Other tactics have been
reported, not necessarily based on contract restrictions.10
Such tactics may include requesting investigators/authors
to withhold publication of the trial data until after an
additional trial, claiming that the drug dosage or device
design or deployment were not optimized. Finally, investi-
gators have been threatened with legal action or subjected
to harassment by companies when attempting to proceed
with scientific publication against the company’s will.2,6,9
Investigators would obviously be well advised to care-
fully read over the entire contract and pay particular atten-
tion to certain details, especially whether his or her access to
the data and right to publish important aspects (with coin-
vestigators) is inappropriately restricted by the agreement.
Clauses in the contract dealing with publication rights,
confidentiality, intellectual property, access to data, and
conflict resolution in particular should be carefully re-
viewed, to ensure patient safety through prompt access to
data and to guard the scientific freedom of the investigator.
Currently, however, only a small minority of investigators
applies this degree of scrutiny to research contracts, and few
take issue with potential points of conflict. Some may not
bother to read carefully what they sign, assuming it to be a
standard contract, or are too trusting and rely on apparent
good intentions. Others simply may not understand the full
legal and ethical implications of the offered contract, and
either do not have the resources to obtain legal advice, or
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do not bother to use them, if they’re available. Others may
feel that access to new treatments will advance their careers
and/or practice and are not truly concerned about their
academic freedom. University-based investigators may not
receive the kind of advice they need and deserve on these
matters from the university’s research offices or the univer-
sity’s legal staff, who may not routinely scrutinize research
contracts in these regards. Others may fear being consid-
ered a troublemaker and not being recruited into an other-
wise good trial, so they choose not to take issue with the
contract.
Thus, while the simple advice to carefully read the
research contract and obtain proper legal counsel before
signing is sound, it is not followed often enough to provide
a simple solution to the problem. For a combination of
reasons, the rights of clinical investigators in industry-
supported clinical trials are generally not well protected at
this point in time and this is currently causing significant
enough problems that other potential solutions deserve
consideration.
POTENTIAL SOLUTIONS
There is no single solution to this problem, but a
number of approaches could contribute significantly to its
resolution under certain circumstances. They include (1)
better functioning trial oversight committees, (2) negoti-
ating noninterference pledges from industry sponsors, (3) a
more active participation by the primary investigator’s
(PI’s) institution in monitoring these aspects of research
contracts, and (4) support of investigators’ rights by pro-
fessional societies and/or journal editors. A concerted ef-
fort will be required to reassert and defend the principle
that major decisions regarding the analysis and reporting of
the scientific data from a clinical trial should reside with the
investigators, not the industry sponsor.
Use of appropriate trial oversight committees
Duly appointed and properly constituted committees,
independent of sponsor control, to oversee the ethical and
scientific conduct and the reporting of clinical trials would
help solve many of the problems cited, in larger multicenter
trials at least. The committees capable of appropriately
protecting investigators’ rights, as part of their function,
include (1) a steering committee or scientific advisory
board, (2) an independent data and safety monitoring
committee, and (3) a publications committee. In larger
multicenter trials, it is appropriate and necessary for PIs to
delegate or entrust some individual rights to the group as a
whole. In exchange, they have a right to expect that the
committees representing the investigators as a group will
respect and defend these rights. The constitution and ap-
propriate activities of these committees are briefly summa-
rized here, with particular emphasis on the issues under
discussion.
The steering committee. Steering committees should
be appointed at the outset, as soon as the initial recruitment
of PIs has been completed and before the trial begins, and
should consist of several experienced PIs, elected by their
peers at the initial investigators’ meeting, rather than those
appointed by the industry sponsor, and be chaired by one of
them. They may include one or two ex officio company
representatives. The steering committee should either de-
velop the trial protocol or at least review or modify it, as
appropriate, before the start of the trial (with broad input
from all PIs), to ensure that the trial will achieve its scientific
objectives. Later, it may recommend appropriate additional
participating centers as needed, should advise the company
regarding solutions to problems arising during the course
of the trial, and should assist with center performance and
patient recruiting issues. In regard to investigators’ rights, it
is also appropriate that this committee review the research
contract being offered to the investigators, before the trial
begins, considering the committee’s ability to uphold and
defend the rights discussed below.
Independent oversight committees. Such commit-
tees are primarily formed to protect the patient’s interests
and ensure proper conduct of the trial. They should
promptly disclose to the steering committee unexpected
complications, worrisome early trends, deficiencies in
methodology or statistical power, and other aspects that
might prevent the study from achieving its scientific objec-
tives. They should ensure prompt notification of all inves-
tigators of significant adverse events in the trial. In prospec-
tive randomized trials, typically where the treatment is
being compared with a placebo control or competitive
treatment, in a blinded fashion, such committees apply
appropriate and explicit “stopping rules” to determine
when the study endpoints have been reached. However,
many trials, particularly device trials, cannot be blinded or
even randomized if patients seeking a new device will not
comply with the randomization. Nevertheless, the other
oversight functions are still necessary. In the absence of a
formal data and safety monitoring committee, an independ-
ent clinical events committee can be formed that bears the
responsibility of analyzing all complications and deaths of
patients within the trail, to determine whether an event is
related to the study or independent of the study. In some
trials, the independent oversight committee may assume,
under the broader aegis of a safety and ethics committee,
the additional responsibility of ensuring that PIs adhere to
conflict of interest guidelines, such as that they not hold
stock or stock options in the company sponsoring the
clinical research trial in which they are involved and do not
receive other financial considerations in exchange for their
participation, which might contribute to a conflict of inter-
est. They should also ensure that the PIs are not participat-
ing in other, similar trials that may lead to patient selection
and steering. Regardless of the official name or specific
duties of the independent oversight committee, it should
consist of respected persons with trial experience and no
connection or vested interest in the trial.
The publications committee. Publications commit-
tees should consist of several experienced PIs elected by
their peers, be chaired by one of the PIs, and include one or
two ex officio company representatives. This committee
should also be elected at the outset of the trial. They should
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decide on appropriate and timely publication(s) of the
study results and their authorship, oppose duplicate publi-
cation practices, review other proposals for publication,
such as reports of single-center data, or reports on specific
aspects using data subsets, review appropriateness of pro-
posed secondary projects, and support the investigators’
rights to analyze and report the scientific data while pro-
tecting the company’s proprietary interests and guarding
against revelations of its business practices, in other words,
try to referee publication conflicts between company and
PIs. It is appropriate that PIs agree at the onset not to
publish their individual experiences without approval of the
publications committee. Single-center experiences may
lack power and not accurately reflect the overall trial expe-
rience. On the other hand, they may be justified as demon-
strating some unique aspect, such as a significant adverse
event or its successful management, or an important tech-
nical modification.
A voluntary company noninterference pledge
To reduce the chance that a company might attempt to
control the scientific aspects of the trial, including the
conduct of the protocol and the analysis and reporting of its
results, it would be immensely helpful if the company
would voluntarily include a noninterference pledge in the
contract. The following statement would be appropriate:
“Neither the company nor its research, marketing, or legal
representatives will interfere in any way with full analysis
and timely presentation or publication of scientific trial data
by the investigators, presuming such data is scientifically
valid and does not contain truly proprietary information.
The interpretation of scientific data will be left up to the
investigators, with prior approval only of an appropriately
constituted publications committee.” Such a broad uni-
form statement, if widely supported by organized medi-
cine, might be an effective basis for negotiations at the
outset of a trial. Indeed, such statements have been in-
cluded in contractual agreements between investigators
and the sponsors of some clinical research trials.11 Clearly,
it would help if research-oriented professional societies
were to stand behind such a statement.
A more active role by the PI’s institution through its
research offices and its institutional review board in
reviewing research contracts
Research contracts appropriately must pass review by
the research offices and institutional review boards of each
PI’s institution. Both should take a more active role in
monitoring this particular aspect. The office of research
could enlist the university’s legal counsel to scrutinize every
such contract with specific regard to inappropriate limita-
tions on the investigators’ rights to publish, as outlined in
the above discussion. The institutional review board obvi-
ously has a right to scrutinize these contracts from the point
of view of patients’ rights (eg, reporting of adverse events)
but additionally in regard to the commitment implicit in
most informed consents that the results of the research will
be disseminated for the benefit of future patients. Any
clauses that might restrict the investigators’ rights to par-
ticipate in prompt and full disclosure of the trial’s results,
independent of sponsor control, could be opposed by them
from the outset.
The promulgation and support of basic investigators’
rights by professional societies and journal editors
Another potentially effective approach would be for the
editors of scientific journals in which these trials are re-
ported to develop widely accepted generic principles that
would protect the rights of scientific investigators. In fact,
the editors of several leading medical journals have recently
published a joint statement appearing in their September
2001 issues.12 This approach is now policy of the Journal of
Vascular Surgery.13 These editors stated that they “strongly
oppose contractual agreements that deny investigators the
right to examine the data independently or to submit a
manuscript for publication without first obtaining the con-
sent of the sponsor.” These journal editors intend to exert
some control over this process and declared they would
“routinely require authors to disclose details of their own
and the sponsor’s role in the study” and many will “ask the
responsible author to sign a statement indicating that he or
she accepts full responsibility for the conduct of the trial,
had access to the data, and controlled the decision to
publish.” This position, that journal editors may choose
not to publish an article if the sponsor had inappropriate
control over trial methodology, data acquisition, data anal-
ysis, and/or publication, is supported by the May 11, 2001,
revision of the section on “Potential Conflicts of Interest
Related to Project Support,” to be included in the next
published version of “Uniform Requirements for Manu-
scripts Submitted to Biomedical Journals.”
This certainly should add strength to the investigator’s
position in negotiating contracts—if they and their industry
sponsors want the papers emanating from the clinical trial
to be published in top-level journals. A similar position
statement has been developed by the editors of 19 surgical
journals for joint publication in June of this year.
WHAT INVESTIGATORS’ RIGHTS DESERVE
CONSIDERATION?
Even if position statements are jointly made by journal
editors and/or professional societies, noninterference
pledges are negotiated, and trial oversight committees are
properly constituted and take the responsibility of support-
ing investigators’ rights seriously, the basic investigators’
rights in question still need to be delineated and promul-
gated, and to our knowledge this has not previously been
done.
The following, as qualified in italics, represent basic
investigators’ rights that we feel are worthy of consider-
ation in drawing up or reviewing any contractual agreement
between clinical research investigator and study sponsor.
The right to prompt notification of significant ad-
verse events in the trial. This is needed in order to fulfill the
investigators’ obligations to patients’ safety and to the insti-
tutional review board that has the responsibility to monitor
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the trial in individual institutions. Such notification should
include full details on new events and frequent detailed
updates on already recognized problems, including their
incidence and prevalence. This is clearly the purview of a
properly constituted safety and monitoring committee in
large multicenter trials.
The right to examine and analyze the primary trial
data independently. This is needed to check the validity of
summarized data and to perform independent statistical
analyses, for the purpose of presentation/publication of trial
results by the investigators. Access to correlative clinical data
might also be needed to perform cost analyses of positive or
equivalent trials, if this might significantly affect the appli-
cation of the new device or drug. Again, this right would
normally come under the jurisdiction of a properly consti-
tuted publications committee in a large multicenter trial.
Those publishing the results of a trial are responsible for the
validity of the data and its analysis. It is not possible to
completely fulfill these responsibilities if the company spon-
soring the trial collects the primary data from the centers,
analyzes it internally using its own statistician and methods,
and presents only summarized data to the investigators. If
the data are broken down by center, it is possible for the
investigators from one or more centers to do at least a
partial validation against the center’s own records. Never-
theless, the investigators responsible for preparing the data
for publication must have access to the primary (raw) data
to do their own data validation and analyses. In smaller
trials and clinical studies, where there is no publications
committee, this right must be guaranteed under the con-
tract.
The right to present and publish trial data in a
timely fashion, regardless of the outcome of the trial.
This includes publishing the results of a negative trial. This
is important to avoid continued harmful or ineffective pa-
tient treatments or to avoid repetition of a similar trial by
others unaware of these results. Ordinarily, the trial sponsor
should have the right to review the manuscript for 30 to 60
days for purposes of patency protection. Delay beyond this
period of time is unnecessary. Any other control over the
publication of scientific trial data, by the terms of a contract
or other means (eg, delaying tactics, legal harassment), is
inappropriate.
The right to publish the experience of one’s own
center. In a multicenter trial, this individual right is nor-
mally surrendered to the group and falls under the jurisdic-
tion of a duly and properly constituted publications com-
mittee. Indeed, it might also be appropriate for the
program committees of scientific societies, reviewing and
selecting abstracts for their scientific sessions, to obtain
assurance from authors that single-center reports of trial
data have received approval from the trial’s publications
committee. The right to publish one’s own data may be
appropriate in the absence of a duly constituted publications
committee, if a decision was made not to publish the overall
trial outcome, or if the center’s experience was unique in some
significant way. For example, one or more center’s experience
with a particular aspect of the trial, such as a complication or
other adverse event, or even its overall outcome, if the experi-
ence is large or unique enough in some regard, may deserve
separate publication, and a request should then be made to
do so. In the absence of a proper publications committee to
mediate this request, the center should have the right to publish
its own data. This would also be the case if the trial sponsor
does not support the publication of a negative trial and the
data of one center (or of several individual centers combining
their own data) are sufficient to allow valid conclusions to be
drawn about some endpoints or other scientific aspects of the
trial.
The right to present or publish independent con-
clusions regarding a trial outcome without company
interference. This situation could arise if there was a bona
fide intellectual disagreement by a significant number of
investigators with the published results and conclusions of the
trial. Again, publication of the results of a trial ordinarily
should be the purview of a properly appointed publications
committee, which would decide on authorship and review
and approve the submitted manuscript. This “right” is
included because of documented conflicts over the publi-
cation of trial results that have stemmed from company
involvement/interference with this process. Clearly, some
publications committees are not properly constituted, be-
ing primarily appointed by the company sponsor or domi-
nated by their own representatives sitting on the commit-
tee, but there have been instances of major disagreement
with favorable publications of trial outcomes with an exam-
ple cited in which the authors of the original trial report
were replaced by the company sponsor in favor of a second
group, holding up the first manuscript while a second more
favorable report was prepared and submitted.6 Generally,
such an independent report would follow the initial pub-
lished report and focus on the evidence from the authors’
experiences within that trial that justify different conclu-
sions.
The authors recognize that many, if not most, clinical
trials that are supported by industry are well run and fairly
conducted, and the analysis and publication of the scientific
data emanating from the trial are not interfered with. This
editorial is aimed at the practices of other sponsors who
attempt to exert control over a trial beyond that necessary
to protect their proprietary interests and the security of
information regarding their business practices, and it is in
recognition of an increasing trend toward control of device
and drug trials by industry sponsors and the belief that the
pendulum needs to swing back the other way to guarantee
investigators appropriate control of the scientific aspects of
clinical trials.
The authors acknowledge constructive reviews by Drs
Kenneth Ouriel, Bruce Perler, and John V White.
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